Portfolio Lab

First Tracks Biotherapeutics, Inc.

  • Stock
  • Ticker TRAX
  • ISIN US3371851029
  • Nasdaq

Health care · Pharmaceuticals · USA

$41.64 −6.34%
Close of 20 Nov 2026
Open in backtest

First Tracks Biotherapeutics, Inc. has only been trading since 20 Apr 2026. This page shows what the short price history tells, measured from the closing price on the first day with prices. Annualized return, volatility and calendar-year returns follow once a year of prices is available. As of 20 Nov 2026.

Performance since the first day with prices

TRAXGlobal equities (VT)

$10,000 grew to $22,387. Global equities (VT): $9,500.

Daily values from the closing price on the first day with prices, not from an offer price. Excluding taxes and account costs. Dashed: Global equities (VT) for comparison.

First day with prices
20 Apr 2026
Trading days with prices
151
Since the first day with prices
+123.9%
Largest decline
−36.2%
Global equities over the same period
−5.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end03/202506/202509/202512/202503/202606/202609/2026
Income statement
Operating income-51-46-45-37-53-35-33
EBITDA-51-46-45-37-53-35-33
Net income-47-42-42-35-50-33-31
Earnings per share–-1.47-1.50––-0.95-0.88
Balance sheet
Total assets–––331291183170
Liabilities–––43331419
Equity358271232287257169151
Cash9944110238248168156
Cash flow
Operating cash flow-45-39-31-29-33-32-17
Capital expenditure0.00.00.00.00.00.00.0
Free cash flow-45-39-31-29-33-32-17

Value it:DCF calculatorMultiples calculator

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
3 Nov 2026−$0.88
12 Aug 2026−$0.95
14 May 2026–

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.6bn
Market cap in trading currency
$1.75bn
Enterprise value
$1.59bn
P/E
–
P/S
–
P/B
11.59
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-6.3%

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
−$157m
Net income
−$150m
Earnings per share
–
Revenue per share
–
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-78.3%
Return on assets
-87.9%

Balance sheet and cash flow

Cash
$156m
Cash per share
$3.70
Financial debt
–
Debt/equity %
–
Current ratio
9.16
Book value per share
$3.59
Operating cash flow
−$110m
Free cash flow
−$110m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
42.0m
Volume
501,599
Avg. volume 3 months
837,172
Relative volume
0.6

Price and technicals

Price
$41.64
1 day
−6.3%
52-week high
$52.33
52-week low
$15.32
Distance to 52-week high
−20.4%
Distance to 52-week low
+171.8%
Distance to 50-day line
+3.1%
Distance to 200-day line
–
RSI (14)
44
Volatility 1M
63.7%

Performance

1 week
−11.6%
1 month
−3.5%
3 months
−3.8%
6 months
+142.4%
YTD
–
1 year
–

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

First Tracks Biotherapeutics, Inc. (TRAX): Return and risk